<DOC>
	<DOCNO>NCT00144612</DOCNO>
	<brief_summary>An open-label , extension , Phase III study evaluate long-term safety efficacy MRA patient sJIA participate Studies MRA011JP MRA316JP</brief_summary>
	<brief_title>Long-term Treatment Study MRA Systemic Juvenile Idiopathic Arthritis ( sJIA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>Inclusion criterion ( MRA011JP patient ) Of patient receive three infusion MRA dose main evaluation period previous study currently continue treatment period patient confirm drug effective problem safety ( MRA316JP patient ) Patients proceed blind period last observation do study completion withdrawal Patients receive three infusion openlabel period meet criterion transition blind period Exclusion criterion Patients enrol 3 month completion previous study Patients treat infliximab etanercept completion previous study start treatment study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>